Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|April 1, 2020
TrialX Launches Covid Labs
Advertisement
TrialX, a NYC-based life sciences technology company has launched Covid Labs, an open platform made up of computer scientists, informaticians, data scientists and designers that are banding together across organizations to solve unique challenges posed by the COVID-19 pandemic. The initiative aims to enable individuals, healthcare agencies, life sciences companies and governments to leverage the power of data, web and mobile technologies to understand and tackle this global crisis.
Dr. Sharib Khan, Co-founder and CEO of TrialX, who kickstarted this initiative mentioned, “As we face a once in a lifetime pandemic, the speed at which the COVID-19 has spread globally, requires the same agility in how we respond to it. Whether it be social distancing to ‘flatten the curve’, or staying up all night, to hack open data sets or re-package existing code, the crisis is a rallying cry for all of us to pitch in.”
In the spirit of “hacking” the pandemic, the lab has already launched several projects including CovidClinicalTrials.com, a global clinical trials tracker displaying a dashboard of all ongoing/planned COVID clinical trials and new treatments and vaccines being investigated by sponsors and research universities. The website provides resources for patients to find and contact research centers near them. The lab has also created a cross-platform symptom tracker app based on Apple’s ResearchKit and Android ResearchDroid to allow investigators and researchers to launch research studies for tracking symptoms related to COVID-19. To increase awareness, the lab hosted a discussion on living with Covid-19 on the CureTalks online radio show that features leading experts and patient advocates.
The lab has an open invite to individuals with a passion for life sciences, public health, data and technology to leverage their skills to hack this pandemic.
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5